<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01507194</url>
  </required_header>
  <id_info>
    <org_study_id>VNK115640</org_study_id>
    <nct_id>NCT01507194</nct_id>
  </id_info>
  <brief_title>A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)</brief_title>
  <official_title>A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 mg) Dose of the Neurokinin-1 Receptor Antagonist, Vestipitant (GW597599), Compared With a Single 4 mg Intravenous Ondansetron Hydrochloride Dose for the Treatment of Breakthrough Post-Operative Nausea and Vomiting After Failed Prophylaxis With an Ondansetron-Containing Regimen in Patients Undergoing Non-Emergency Surgical Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accenture</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accenture</source>
  <brief_summary>
    <textblock>
      This study will evaluate single IV doses of Vestipitant (GW597599) compared to 4 mg IV
      ondansetron for treating breakthrough postoperative nausea and vomiting (PONV) after failure
      of PONV prophylaxis with a regimen that includes 4 mg IV ondansetron.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>10 min. after infusion start through 24 hrs. or discharge</time_frame>
    <description>No emesis and no further rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea Numeric Rating Scale (NNRS)</measure>
    <time_frame>Pre-dose; 5, 10, 15 min. post-dose; q 15 min. through 2 hrs. post-dose; q 2 hrs. through 24 hrs. post-dose; and 5 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No Emesis/Vomiting</measure>
    <time_frame>Pre-dose; continuous through 24 hrs. post-dose; and 5 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Ondansetron 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vestipitant 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vestipitant 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vestipitant 18 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vestipitant 24 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vestipitant 36 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Single IV dose</description>
    <arm_group_label>Ondansetron 4 mg</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vestipitant</intervention_name>
    <description>Single IV dose</description>
    <arm_group_label>Vestipitant 6 mg</arm_group_label>
    <arm_group_label>Vestipitant 12 mg</arm_group_label>
    <arm_group_label>Vestipitant 18 mg</arm_group_label>
    <arm_group_label>Vestipitant 24 mg</arm_group_label>
    <arm_group_label>Vestipitant 36 mg</arm_group_label>
    <other_name>GW597599</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female post-operative surgical subjects between the ages of 18-75 years.

          -  Female subject is of non-childbearing potential or of child-bearing potential and
             agrees to use specified contraception methods.

          -  Has 3 or more of the following independent risk factors for PONV: female gender;
             non-smoker; history of PONV or motion sickness; or planned post- operative opioids.

          -  Has received one dose of ondansetron as part of a PONV prophylaxis regimen for the
             surgical procedure.

          -  Has received general anesthesia.

          -  Meets ASA Physical Status Classification of 1 or 2 without an &quot;E&quot; modifier
             preoperatively on the day of surgery and has hematology and blood chemistry values
             within acceptable limits for surgery.

          -  Is capable of giving written informed consent.

          -  Experiences breakthrough PONV defined as: post-operative nausea of â‰¥ 7 on the Nausea
             Numeric Rating Scale; nausea resulting in a subject request for an anti-emetic; or an
             episode of emesis or retching.

        Exclusion Criteria:

          -  A history of HIV.

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of Screening.

          -  An ALT or AST &gt;2.5 x ULN at Screening.

          -  Pregnant or lactating females.

          -  The subject is scheduled to undergo a laparoscopic biopsy only.

          -  The subject has a history of or is scheduled to undergo cardiac/cardiothoracic
             surgery.

          -  The subject is scheduled to receive neuraxial anesthesia(e.g., epidural, spinal, or
             caudal anesthesia)or total IV anesthesia.

          -  The subject is scheduled to receive propofol for maintenance of anesthesia (propofol
             as an induction agent is allowed).

          -  The subject is scheduled to receive an NK1 inhibitor (aprepitant/fosaprepitant) as
             part of a PONV prophylaxis regimen for the surgical procedure.

          -  The subject is scheduled to have gastric contents suctioned continuously during the
             surgical procedure via a nasogastric tube, or a nasogastric or oral gastric tube
             during the post-operative period. A single pass at the beginning or at the end of the
             procedure, and intraoperative gastric suctioning of air, will be permitted.

          -  The subject received an investigational drug within 30 days or was scheduled to
             receive any investigational drug in addition to vestipitant during the study period.

          -  The subject has persistent or recurrent nausea and/or vomiting due to other
             etiologies, including, but not limited to, gastric outlet obstruction, hypercalcemia,
             active peptic ulcer, increased intracranial pressure, chemotherapy, or brain
             metastases.

          -  The subject received radiation therapy to the abdomen or the pelvis within 7 days
             prior to receiving study medications and/or received radiation therapy to the abdomen
             or the pelvis in the evaluation period.

          -  The subject has a history of wound dehiscence.

          -  The subject has a history of any other illness which might pose an unacceptable risk
             by administering study medication.

          -  The subject has any current or past medical condition (e.g., vagotomy) and/or required
             medication to treat a condition that could affect the evaluation of the study.

          -  The subject has a known contraindication or hypersensitivity to ondansetron or
             ondansetron injection, any scheduled anaesthetic or analgesic agents, vestipitant or
             any component of the vestipitant formulation including Captisol.

          -  The subject received medication with known or potential antiemetic activity after the
             induction of anaesthesia (during the intraoperative or post- operative period) other
             than the planned Study Treatment.

          -  Current or planned use of strong or moderate inhibitors of CYP3A within 7 days or
             inducers of CYP3A within 14 days prior to study medication administration.

          -  The subject is unwilling or unable to follow the procedures outlined in the protocol.

          -  The subject is mentally or legally incapacitated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Brigandi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Trials</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Anesthesia (St. Elizabeth's Medical Center)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Anesthesia at Forsyth Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>September 30, 2012</last_update_submitted>
  <last_update_submitted_qc>September 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Vestipitant</mesh_term>
    <mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

